Boston Historical Balance Sheet

0HOY Stock

90.94 1.30 1.45%

Trend analysis of Boston Scientific Corp balance sheet accounts such as Other Current Liab of 2.8 B, Total Current Liabilities of 4.1 B or Total Stockholder Equity of 12 B provides information on Boston Scientific's total assets, liabilities, and equity, which is the actual value of Boston Scientific Corp to its prevalent stockholders. By breaking down trends over time using Boston Scientific balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Boston Scientific Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Boston Scientific Corp is a good buy for the upcoming year.

Boston Scientific Inventory

1.45 Billion

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boston Scientific Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Boston Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Boston Scientific Corp at a specified time, usually calculated after every quarter, six months, or one year. Boston Scientific Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Boston Scientific and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Boston currently owns. An asset can also be divided into two categories, current and non-current.

Boston Scientific Balance Sheet Chart

At this time, Boston Scientific's Short Term Investments are comparatively stable compared to the past year. Short Term Debt is likely to gain to about 711.3 M in 2024, whereas Other Current Liabilities is likely to drop slightly above 2.8 B in 2024.

Total Assets Other Current Liab Total Stockholder Equity Retained Earnings Other Assets Good Will

Total Assets

Total assets refers to the total amount of Boston Scientific assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Boston Scientific Corp books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Good Will

An intangible asset that arises when a company acquires another business for more than the fair market value of its net identifiable assets, representing the value of the brand, customer base, and other intangible factors.

Most accounts from Boston Scientific's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Boston Scientific Corp current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boston Scientific Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	2.7B	2.4B	3.2B	2.8B
Total Assets	32.2B	32.5B	35.1B	26.4B

Other Current Liab Total Assets

Boston Scientific balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Short Long Term Debt Total	Short Term Investments
Total Assets		0.55	0.59	0.99	0.98	0.82	0.94	0.9	0.71	1.0	0.51	0.95	0.71	0.9	0.97	0.63	0.83	0.92	0.57	0.91	0.96	0.95	0.31	0.78	0.96	0.67
Other Current Liab	0.55		0.9	0.49	0.54	0.75	0.5	0.67	0.57	0.55	0.75	0.49	0.57	0.68	0.56	0.34	0.58	0.56	0.06	0.49	0.65	0.59	0.05	0.64	0.63	0.88
Total Current Liabilities	0.59	0.9		0.52	0.56	0.75	0.53	0.67	0.55	0.59	0.67	0.49	0.55	0.75	0.6	0.39	0.51	0.59	-0.06	0.47	0.68	0.57	0.23	0.55	0.68	0.81
Total Stockholder Equity	0.99	0.49	0.52		0.99	0.76	0.93	0.91	0.69	0.99	0.46	0.93	0.69	0.88	0.98	0.63	0.78	0.93	0.59	0.93	0.91	0.95	0.22	0.79	0.92	0.6
Property Plant And Equipment Net	0.98	0.54	0.56	0.99		0.76	0.94	0.93	0.65	0.98	0.49	0.92	0.65	0.91	0.99	0.65	0.76	0.96	0.53	0.94	0.9	0.94	0.2	0.84	0.9	0.62
Net Debt	0.82	0.75	0.75	0.76	0.76		0.74	0.74	0.6	0.82	0.85	0.76	0.6	0.84	0.78	0.32	0.94	0.76	0.33	0.65	0.88	0.77	0.32	0.72	0.89	0.83
Retained Earnings	0.94	0.5	0.53	0.93	0.94	0.74		0.85	0.63	0.94	0.52	0.99	0.63	0.87	0.92	0.8	0.77	0.88	0.52	0.95	0.9	0.89	0.35	0.82	0.9	0.64
Accounts Payable	0.9	0.67	0.67	0.91	0.93	0.74	0.85		0.66	0.9	0.55	0.81	0.65	0.92	0.95	0.6	0.69	0.92	0.32	0.88	0.82	0.86	0.05	0.81	0.82	0.68
Cash	0.71	0.57	0.55	0.69	0.65	0.6	0.63	0.66		0.67	0.46	0.65	1.0	0.49	0.65	0.39	0.65	0.49	0.66	0.71	0.71	0.85	-0.06	0.52	0.71	0.57
Non Current Assets Total	1.0	0.55	0.59	0.99	0.98	0.82	0.94	0.9	0.67		0.51	0.94	0.67	0.92	0.97	0.63	0.83	0.93	0.53	0.89	0.96	0.93	0.35	0.76	0.97	0.67
Non Currrent Assets Other	0.51	0.75	0.67	0.46	0.49	0.85	0.52	0.55	0.46	0.51		0.52	0.46	0.61	0.53	0.17	0.78	0.54	0.15	0.47	0.58	0.55	0.01	0.73	0.58	0.74
Other Assets	0.95	0.49	0.49	0.93	0.92	0.76	0.99	0.81	0.65	0.94	0.52		0.65	0.83	0.9	0.75	0.82	0.85	0.59	0.92	0.93	0.9	0.4	0.78	0.91	0.63
Cash And Short Term Investments	0.71	0.57	0.55	0.69	0.65	0.6	0.63	0.65	1.0	0.67	0.46	0.65		0.49	0.65	0.39	0.65	0.49	0.66	0.71	0.71	0.85	-0.06	0.52	0.71	0.57
Net Receivables	0.9	0.68	0.75	0.88	0.91	0.84	0.87	0.92	0.49	0.92	0.61	0.83	0.49		0.94	0.64	0.72	0.94	0.19	0.81	0.87	0.79	0.33	0.81	0.88	0.75
Good Will	0.97	0.56	0.6	0.98	0.99	0.78	0.92	0.95	0.65	0.97	0.53	0.9	0.65	0.94		0.64	0.76	0.97	0.46	0.93	0.89	0.92	0.19	0.83	0.91	0.67
Common Stock Shares Outstanding	0.63	0.34	0.39	0.63	0.65	0.32	0.8	0.6	0.39	0.63	0.17	0.75	0.39	0.64	0.64		0.29	0.6	0.26	0.78	0.59	0.57	0.34	0.59	0.58	0.49
Non Current Liabilities Total	0.83	0.58	0.51	0.78	0.76	0.94	0.77	0.69	0.65	0.83	0.78	0.82	0.65	0.72	0.76	0.29		0.71	0.56	0.69	0.87	0.81	0.29	0.7	0.87	0.71
Inventory	0.92	0.56	0.59	0.93	0.96	0.76	0.88	0.92	0.49	0.93	0.54	0.85	0.49	0.94	0.97	0.6	0.71		0.35	0.87	0.83	0.85	0.18	0.88	0.84	0.63
Other Current Assets	0.57	0.06	-0.06	0.59	0.53	0.33	0.52	0.32	0.66	0.53	0.15	0.59	0.66	0.19	0.46	0.26	0.56	0.35		0.61	0.5	0.71	-0.06	0.38	0.52	0.19
Other Stockholder Equity	0.91	0.49	0.47	0.93	0.94	0.65	0.95	0.88	0.71	0.89	0.47	0.92	0.71	0.81	0.93	0.78	0.69	0.87	0.61		0.81	0.92	0.06	0.85	0.82	0.62
Total Liab	0.96	0.65	0.68	0.91	0.9	0.88	0.9	0.82	0.71	0.96	0.58	0.93	0.71	0.87	0.89	0.59	0.87	0.83	0.5	0.81		0.9	0.48	0.7	0.99	0.77
Total Current Assets	0.95	0.59	0.57	0.95	0.94	0.77	0.89	0.86	0.85	0.93	0.55	0.9	0.85	0.79	0.92	0.57	0.81	0.85	0.71	0.92	0.9		0.1	0.8	0.91	0.66
Intangible Assets	0.31	0.05	0.23	0.22	0.2	0.32	0.35	0.05	-0.06	0.35	0.01	0.4	-0.06	0.33	0.19	0.34	0.29	0.18	-0.06	0.06	0.48	0.1		-0.04	0.45	0.23
Common Stock	0.78	0.64	0.55	0.79	0.84	0.72	0.82	0.81	0.52	0.76	0.73	0.78	0.52	0.81	0.83	0.59	0.7	0.88	0.38	0.85	0.7	0.8	-0.04		0.7	0.66
Short Long Term Debt Total	0.96	0.63	0.68	0.92	0.9	0.89	0.9	0.82	0.71	0.97	0.58	0.91	0.71	0.88	0.91	0.58	0.87	0.84	0.52	0.82	0.99	0.91	0.45	0.7		0.78
Short Term Investments	0.67	0.88	0.81	0.6	0.62	0.83	0.64	0.68	0.57	0.67	0.74	0.63	0.57	0.75	0.67	0.49	0.71	0.63	0.19	0.62	0.77	0.66	0.23	0.66	0.78

Click cells to compare fundamentals

Boston Scientific Account Relationship Matchups

Boston Scientific balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	30.6B	30.8B	32.2B	32.5B	35.1B	26.4B
Other Current Liab	2.7B	2.8B	2.7B	2.4B	3.2B	2.8B
Total Current Liabilities	4.9B	3.7B	4.3B	3.8B	4.9B	4.1B
Total Stockholder Equity	13.9B	15.3B	16.6B	17.6B	19.3B	12.0B
Property Plant And Equipment Net	2.4B	2.5B	2.7B	2.8B	3.3B	2.3B
Net Debt	9.8B	7.7B	7.4B	8.2B	8.7B	6.5B
Retained Earnings	(2.3B)	(2.4B)	(1.4B)	(750M)	819M	860.0M
Accounts Payable	542M	513M	794M	862M	942M	543.4M
Cash	563M	1.9B	2.1B	1.1B	865M	927.8M
Non Current Assets Total	25.9B	24.1B	25.9B	26.7B	28.6B	21.4B
Non Currrent Assets Other	144M	166M	225M	442M	4.5B	4.7B
Other Assets	4.6B	4.5B	4.6B	4.6B	5.3B	5.5B
Cash And Short Term Investments	563M	1.9B	2.1B	1.1B	865M	928.1M
Net Receivables	1.9B	1.5B	1.8B	2.0B	2.2B	1.7B
Good Will	10.2B	10.0B	12.0B	12.9B	14.4B	9.6B
Common Stock Shares Outstanding	1.4B	1.4B	1.4B	1.4B	1.5B	1.5B
Non Current Liabilities Total	11.8B	11.8B	11.3B	11.1B	10.7B	9.8B
Inventory	1.6B	1.4B	1.6B	1.9B	2.5B	1.5B
Other Current Assets	624M	2.3B	1.2B	1.3B	937M	949.8M
Other Stockholder Equity	15.8B	17.5B	17.7B	18.0B	18.4B	17.8B
Total Liab	16.7B	15.5B	15.6B	14.9B	15.6B	14.4B
Total Current Assets	4.7B	6.7B	6.3B	5.8B	6.5B	5.0B
Intangible Assets	8.2B	6.1B	6.2B	6.0B	6.0B	6.8B
Short Long Term Debt Total	10.4B	9.6B	9.5B	9.3B	9.6B	8.1B
Liabilities And Stockholders Equity	30.6B	30.8B	32.2B	32.5B	35.1B	27.1B
Accumulated Other Comprehensive Income	270M	207M	263M	268M	50M	47.5M
Short Term Debt	1.5B	83M	332M	81M	607M	711.3M
Long Term Debt	3.8B	4.8B	8.6B	9.1B	10.5B	7.0B
Capital Surpluse	17.2B	17.3B	17.6B	19.7B	22.7B	19.5B
Property Plant Equipment	2.4B	2.5B	2.7B	2.8B	3.3B	2.4B
Other Liab	3.0B	2.2B	2.1B	1.8B	1.6B	1.9B
Net Tangible Assets	(4.5B)	(760M)	(1.6B)	(1.3B)	(1.5B)	(1.6B)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Boston Stock Analysis

When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC